Esophageal Diseases  >>  Xolair (omalizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xolair (omalizumab) / Roche, Novartis
NCT00084097: Omalizumab to Treat Eosinophilic Gastroenteritis

Completed
2
30
US
Omalizumab
National Institute of Allergy and Infectious Diseases (NIAID)
Gastroenteritis
 
02/07
NCT00123630: A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab

Completed
2
30
US
omalizumab, Xolair, Placebo, saline
University of Utah, Novartis Pharmaceuticals
Esophagitis
01/10
01/10

Download Options